CRISPR’s Clinical Leap: Strengthening Risk and Audit Practices
The healthcare industry is witnessing what many experts consider to be a once-in-a-generation breakthrough.
ERM
Understanding the GLP-1 Revolution: A Guide for Risk and Compliance Leaders
The healthcare industry is witnessing what many experts consider to be a once-in-a-generation breakthrough.
Maximizing M&A Success in Healthcare: The Essential Role of Risk Management
This observation is particularly relevant for the healthcare industry at the moment: while deal-making excitement builds, recent history serves as a sobering reminder of what’s at stake.
ERM: Marketing Hype or Value-Add? A Review of the Empirical Data
The practice of Enterprise Risk Management (ERM) has become widely adopted in most large organizations, including within the pharmaceuticals sector. But is it just another management fad, a piece of marketing hype promoted by academics and consultants, or does it genuinely add value to organizations? In this post, we’ll take a critical look at the empirical data to uncover the truth about ERM’s impact.
Five Factors Holding Back ERM in the Pharma Sector
Despite compelling evidence linking robust Enterprise Risk Management (ERM) to improved financial performance and shareholder value (see our blog: Does ERM add value? An objective review of the evidence), many pharma organizations fail to realize its full potential.
From Ankle Bones to Algorithms: A Brief History of Risk Management
Risk is an inseparable part of the human experience. From our earliest ancestors facing the uncertainties of a hunt to modern pharmaceutical companies navigating complex global markets, we’ve always grappled with the unknown and sought to manage it as best we can.